BCG plus mitomycin did not improve disease-free survival versus BCG alone in high-risk non-muscle-invasive bladder cancer patients
Adding mitomycin to bladder cancer treatment did not improve survival compared to bacillus calmette-guerin alone in this trial
This randomized Phase 3 trial enrolled 501 BCG-naive patients with high-grade pTa or any grade pT1 non-muscle-invasive bladder cancer. The s…
Doctors tested adding mitomycin to standard bladder cancer therapy. Patients receiving both drugs did not live longer without disease than t…
